Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs

This study investigated the effects of semaglutide, an incretin mimetic drug, on 27 obese PCOS patients unresponsive to lifestyle modifications. After three months of treatment with 0.5 mg of semaglutide weekly, patients experienced a mean weight loss of 7.6 kg and a BMI reduction of 3.1, with 80% achieving at least a 5% weight reduction. The treatment also improved insulin resistance and normalized fasting blood glucose in 80% of patients with impaired fasting glucose. For those responsive to semaglutide, continued treatment for six months resulted in a total mean weight loss of 11.5 kg and BMI reduction from 34.4 to 29.4, with 80% normalizing menstrual cycles. The study concludes that semaglutide effectively reduces body weight and improves metabolic and reproductive outcomes in obese PCOS patients with minimal side effects.